Results of a randomized controlled trial have suggested a protective effect of
selenium against
prostate cancer. Few other prospective studies have been conducted to confirm or refute this. The association between
prostate cancer and baseline toenail
selenium level was evaluated in the Netherlands Cohort Study, conducted among 58,279 men, aged 55-69 years at entry. In September 1986, the cohort members completed a questionnaire on risk factors for
cancer and provided toenail clippings for determination of baseline
selenium status. After 6.3 years of follow-up, 540 incident prostate
carcinoma cases and 1,211 subcohort members with complete toenail
selenium data were available for case-cohort analyses. In multivariate survival analysis, an inverse association between toenail
selenium level and
prostate cancer risk was observed. Incidence rate ratios in increasing
selenium quintiles were 1.00 (ref), 1.05, 0.69, 0.75, and 0.69 (95% confidence interval, 0.48-0.99), respectively (P-trend=0.008). This association persisted after exclusion of cases diagnosed during early follow-up. The inverse association was more pronounced in ex-smokers than current smokers, and unclear in never-smokers. Analysis of effect modification by intake of
antioxidant vitamins C, E, and the
carotenoids alpha-carotene,
beta-carotene,
beta-cryptoxanthin,
lycopene, and
lutein/
zeaxanthin showed a strong, significant interaction with
beta-cryptoxanthin, and to a lesser extent with
vitamin C. These results confirm the hypothesis that higher
selenium intake may reduce
prostate cancer risk. Future research on optimum dose level is needed.